Prevent Cancer Foundation welcomes 2024 corporate members dedicated to cancer prevention and early detection
FOR IMMEDIATE RELEASE
Kyra Meister
703-836-1746
kyra.meister@preventcancer.org
Alexandria, Va. – The Prevent Cancer Foundation today announced the 13 companies who are members of their Corporate Membership Program’s 2024 cohort. Launched in 2023, the Foundation’s Corporate Membership Program was created with the goal of accelerating mutual goals and reaffirming a commitment from corporate partners to advancing cancer prevention and early detection.
Program members receive access to Foundation resources and exclusive events—including industry roundtable discussions—creating opportunities to collaborate and exchange ideas throughout the year. Membership supports the Foundation’s work in four key areas: research, education, outreach and advocacy.
“Over the last year, the Prevent Cancer Foundation has had the opportunity to see our Corporate Membership Program not only grow, but flourish.” said Jody Hoyos, CEO of the Prevent Cancer Foundation. “Each of these companies supports our mission just as strongly as we do. By creating meaningful partnerships with experts across the industry, we are able to better guide people of screening age toward better outcomes for their health.”
The 2024 class of corporate members, as of the date of this publication, include:
Gold
- Daiichi Sankyo
Silver
- Exact Sciences
- Hologic
Bronze
- AstraZeneca
- Bristol Myers Squibb
- Gilead
- GSK
- Guardant
- Eisai
- Eli Lilly
- Merck
- Natera
- Novartis
- Sanofi
The Corporate Membership Program is open to companies who support the Foundation’s vision of a world where cancer is preventable, detectable and beatable for all. Those interested in learning more about the program or how to join this community can contact Jennifer Niyangoda, Vice President of Development and Marketing, at jennifer.niyangoda@preventcancer.org.
###
About the Prevent Cancer Foundation®
The Prevent Cancer Foundation® is the only U.S.-based nonprofit organization solely dedicated to cancer prevention and early detection. Through research, education, outreach and advocacy, we have helped countless people avoid a cancer diagnosis or detect their cancer early enough to be successfully treated. We are driven by a vision of a world where cancer is preventable, detectable and beatable for all.
The Foundation is rising to meet the challenge of reducing cancer deaths by 40% by 2035. To achieve this, we are committed to investing $20 million for innovative technologies to detect cancer early and advance multi-cancer screening, $10 million to expand cancer screening and vaccination access to medically underserved communities, and $10 million to educate the public about screening and vaccination options.
For more information, please visit www.preventcancer.org.